Conferencia de resultados

T1 del ejercicio fiscal 2027

viernes, 6 de noviembre de 2026 · Antes de la apertura del mercado · 1 analista hizo preguntas

Ramsay Santé informó de un crecimiento de los ingresos y una mejora de la rentabilidad en el T1, y mantuvo sus perspectivas a corto y medio plazo.

Acción el día de la conferencia
−2,4%

Anuncios de la conferencia

  • Propuesta de presidente independiente. Ramsay Santé propondrá a Frédéric Collet como presidente independiente del Consejo de Administración en la junta general anual del 4 de diciembre.
  • Consolidación en el sur de Francia completada. La consolidación prevista en el sur de Francia, que consistía en pasar de tres centros a uno y reducir las camas en aproximadamente 50, se completó según lo previsto el 1 de octubre.
  • Rechazado el presupuesto sanitario francés. La propuesta de presupuesto sanitario francés para 2027, conocida como PLFSS, fue rechazada y devuelta al Parlamento; la dirección señaló que el resultado político era incierto.

Previsiones de la dirección

Qué espera ahora la dirección
Previsiones y perspectivas de RMY0

Desde la conferencia anterior: 6 reafirmadas

Indicador Periodo Previsión Desde la conferencia anterior
Ingresos EF 27 Reafirmada
Ingresos EF 29 Reafirmada
CapEx de crecimiento Próximos 3 años Reafirmada
Deuda neta sobre EBITDA pre-IFRS Objetivo vigente Reafirmada
Expresada en palabras
Margen EBITDA EF 27 Reafirmada
Margen EBITDA EF 29 Reafirmada
Australia · EBIT segundo semestre
Aumento del EPS primeros 12 meses de propiedad
Negocio hospitalario del Reino Unido · Actividad del NHS tercer trimestre del ejercicio '26
Elysium · Impulso de la recuperación segundo semestre
Europa · Actividad segundo semestre
Costos netos de financiación FY '26
Tasa impositiva efectiva subyacente Ajustado año completo
Ratio de distribución de dividendos Ajustado FY '26
Gastos operativos digitales y de datos FY '26
Australia · EBIT FY '26

Que una previsión no se mencione no significa que se haya retirado.

Temas clave

Qué trataron la dirección y los analistas
Temas clave de la conferencia de resultados de RMY0 de T1 del ejercicio fiscal 2027

Se amplían la atención integrada y las herramientas digitales

Nuevo desde 25 feb.

En Suecia, aumentaron las derivaciones desde un hospital central a atención domiciliaria avanzada, cuidados paliativos con hospitalización y rehabilitación; mientras tanto, continuó el despliegue de las herramientas de voz a texto y Ramsay Companion se utilizó más de 100 veces al mes en septiembre.

Preguntas de los analistas

La dirección describió circuitos de atención en el mismo día que incluyen a cuatro especialistas en una unidad, con una mejor remuneración, e indicó que este segmento crecía en un rango del 35% al 40%, no a doble dígito.

Avanza la consolidación de la cartera

La consolidación de centros en el sur de Francia se completó según lo previsto el 1 de octubre: se pasó de tres centros a uno y se redujo el número de camas en aproximadamente 50; también se transfirieron las actividades de Valence y algunos servicios de maternidad.

La dirección hace hincapié en las palancas bajo su control

Ante la incertidumbre sobre el presupuesto sanitario de Francia y las tarifas limitadas, la dirección señaló que sus perspectivas no dependen únicamente del apoyo tarifario y citó como palancas bajo su control los volúmenes, la utilización de la capacidad, las compras, la gestión de la plantilla y la productividad.

Preguntas de los analistas

La dirección mencionó ajustes de plantilla, la reducción del personal temporal y no médico, iniciativas de compras y mejoras en la codificación; las medidas relativas a la cartera podrían generar costes no recurrentes, que espera que sigan siendo bastante limitados.

La dirección señaló que la propuesta de presupuesto sanitario francés para 2027 había sido rechazada y devuelta al Parlamento, y que no especularía sobre el resultado político.

Otras preguntas

La dirección atribuyó el aumento a la estacionalidad habitual del primer trimestre, cuando la actividad no urgente disminuye durante el verano, y señaló que las comparaciones de septiembre con años anteriores muestran una deuda neta menor.

La dirección señaló un cambio hacia la cirugía ambulatoria, con menor remuneración, y unas tarifas limitadas o en descenso; indicó que el crecimiento de los ingresos en Francia fue de alrededor del 2,4%.

La dirección indicó que la cifra corresponde al CapEx bruto total antes del arrendamiento; aproximadamente un 3% se destina a mantenimiento, TI y requisitos regulatorios, y un 1% de media, a desarrollo.

La dirección valoró los inmuebles en EUR 1.5 billion a finales de junio, señaló que representan el 20% de los metros cuadrados operados y situó la deuda asociada en aproximadamente EUR 400 million a finales de septiembre.

Transcripción

Transcripción

16 intervenciones · 3.498 palabras · 2 de la dirección, 1 analistas

Intervenciones preparadas

Operator

Good day, and thank you for standing by. Welcome to the Ramsay Sante Q1 Results Presentation Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speakers today, Pascal Roche, Group CEO; and Clement Lafaix, Group CFO. Please go ahead.

Pascal Roche Dirección

Okay. Thanks a lot. Thanks all of you for joining this Q1 Ramsay Sante conference. So today, as just stated, we will comment to the results we have just been releasing yesterday evening, and I am so with Clement Lafaix, the Group CFO.

Entering into this Q1 results on the Page #4, if we were to summarize in a couple of seconds, we would say that we have delivered a solid Q1 performance with continued revenue growth and improved operational performance. As a matter of fact, the revenue has reached EUR 1.233 billion, which is a plus 2.9% growth versus the same quarter of last year. Would we were to compare in constant currency, it is a 2.6% growth -- what has driven this growth? In fact, it has been driven by higher MSO activity. As an example, for France, the MSO admission has increased by 4.1%, targeted efforts driving a huge increase in day medicine development in France and continued strength in the Nordic. But beyond this growth, we are pleased to share with you that the EBITDA for Q1 has been issued at EUR 121 million versus EUR 112 million last year which represents a 9.8% margin. Please keep in mind that we are talking about Q1 with the seasonality effect of July and August.

So an improved profitability driven beyond this revenue growth by productivity gains, disciplined cost control across all geographies and as you may recall, the rolling out the execution of the St. Goran contract despite all these tariff headwinds. Beyond that, the leverage ratio has decreased versus Q1 last year, continued deleveraging by 0.2 points. We will come back to this later with Clement Lafaix. So in this context, Ramsay Sante, we maintained our short-term and midterm financial outlook.

Besides in this slide, by the way #4, there has been during the last quarter an important business development, a very old, I would say, litigation going back to 2002, 2004 for one of a huge important hospital in Lyon called Jean Mermoz. There was an appeal ruling that took place and that confirm that the group has no liability regarding the topic of the building more than 20 years ago. It means that there is a EUR 57 million in damage that remains to be received pursuant to the decision and subject to further appeal by the opposite, I would say opponent.

So that being said, if we go on the next page, during the Capital Market Day we held on September 17, we have shared with you our ambition for the next years up to 2030, our strategic plan, connecting care 2030 to unlock the full potential of integrated care and reinforcement of the active portfolio management and efficiency measures. So we are pleased to share with you a couple of deliveries that took place during Q1 on the 5 avenues. As an example, in order to keep on strengthening the integrated care offering, in Sweden the referral from a huge central hospital to discharge patients to advance home care, inpatient palliative care and inpatient rehabilitation. So the number of patients that have been proposed when discharged because they needed to be followed by one of a business unit, one of our team has increased by 70% compared this one to Q1 2024, so 2 years ago.

Talking about once again accelerating the additional profitable growth through new revenue stream, pleased to share with you that regarding imaging for France in the last month, we have been rolling out 2 new units, one PET scan and radiotherapy, by the way, in the hospital Peupliers in Paris. Regarding the third pillar, which is digitalization and AI, we keep on rolling full speed regarding the rollout of NB scripts. So speech to text to release, I would say, the administrative burden and to free up some patient time for the doctor. It is done for all the Primerica in Sweden. And now we are increasing the speed in the mental health business unit in France and with our own AI Ramsay companion tool, it once again ticks the box of better medical excellence and better efficiency. As an example, Ramsay Companion there is over 100 per month in September, a couple of days ago.

Talking about portfolio management, we were committed during the CMD to say that in venue South of France, will go from 3 facilities to 1 facility, reducing, by the way, the number of beds by roughly 50 beds, delivering additional EBITDA. It has been done as planned on October 1. And finally, regarding the continued cost optimization initiative, the choosing wisely, which is better for the patient and efficiency is rolling out once again through various country. And 3 weeks ago, we have been relocating the group headquarter. We used to be in Paris. We are now in the suburb of Paris and with a good -- I would say, a good setting.

Another news to share with you on the next slide, during once again, the CMD mid-September regarding the new Board, once again, would the demerger take place and would the Ramsay Sante AGM on December 4 validate this content, new governance framework we were saying. Once again, we confirm that the majority of the Board will be constituted by independent director through a very rigorous process. The Chairman of the Board will be independent. I'm going to come back to this in a couple of seconds. The Chairman of the Audit Committee will be independent and all this refers to the Afep-Medef French Governance Code.

Talking about the Chairman will be proposed, by the way, to the Ramsay Sante AGM, Frederic Collet, Independent Chairman of the Board. Frederic Collet has a long, long experience in the health care industry in France and on the international base, having been the Chairman of Novartis France has been working in Sandoz, the Head of the Oncology worldwide. He has been, by the way, for 4 years in France, the Chairman of the Association of the French pharmaceutical industry.

And by the way, since a couple of years is on the Board of the Institute Imagine, the largest institute for genetic disease in France, key, I would say, institute. He knows well Ramsay Sante because as you know, we are a mission-driven company. He has been part of the last 3 years of this committee and being both is, by the way, Founder and President of BIOnnassay-Consult, Senior Adviser at Eurazeo and Chairman of AI and Cancer Consortium. So this is the key news in a nutshell I wanted to share that to give you more granularity regarding the financial performance during the last 3 months.

I'm giving the floor to Clement.

Clement Lafaix Dirección

Thank you, Pascal. Good morning, good afternoon, everyone. Before presenting the next slide, so a reminder of the key message, revenue growth has been resilient and predominantly volume driven. Underlying profitability has improved at a higher pace than revenues over the last quarter, thanks to performance plans despite a constrained tariff environment, and we continue to deleverage the company.

So if we go to the Page #8. So let us deep dive in a couple of figures. Revenues increased by 2.9% over the last quarter, 2.6% at a constant FX basis, growing in all geographies and all segments of activities. As you can see on this bridge, the growth is exclusively organic driven. Organic revenue growth remained resilient at 2.2% in France with no tariff increase supported by 4.1% increase in MSO volumes. Notably supported by day medicine, a growth that has been quite significant at around plus 40% over the last quarter. And this has been partly offset by the continued negative mix effect with a shift from full hospitalization to ambulatory care. In the Nordics, organic growth is at 4.2%, driven by primary care development as well as St. Goran robust volume as well as the effect of the new contract.

If we go to next page, let's have a look at our profitability. EBITDA has improved by 7.5% over the last quarter versus last year, plus EUR 8 million absolute in spite of increasing inflation and notably in France, minimum wage increase of 2.4% in June '26. And this inflation is not covered by the tariff, notably in France. So how we achieved this profitability improvement? Organic growth, I mentioned it already, St. Goran new contracts in Q1, and we expect to see a further effect in Q2 because we will be on a like-for-like basis on this contract only starting from Jan next year.

And I mentioned it as well structural performance plan and cost containment initiatives. Clearly, in order to navigate a constrained tariff environment, performance and operational execution is key. I will give you a couple of examples of what has been delivered in this area over the quarter. First of all, we mentioned it the imaging units, the 2 new imaging units, so continue to accelerate in this area. I mentioned as well the day medicine care developing at a very significant pace, further improvement in coding accuracy with AI, staff -- nonmedical staff reduction in France over the last quarter.

In the Nordics, very good cost control in pharmaceutical, in primary care, benchmarking between the units and with the use -- further use of generic stress, use of -- that Pascal, you mentioned it. And finally, we made also good progress in our portfolio management with the transfer of the activities of the Valence unit as well as also some transfer of maternity ward. We are not stopping there. Additional actions have already been identified and will continue to accelerate in.

If we go to the next page regarding the leverage, leverage is typically higher in September than in June, reflecting the normal seasonality of the business. Patients do not undertake nonemergency care during the holiday and summer period. But then we compare September with September last year and 2 years ago, as you can see on this graphic, we are continuously deleveraging the company, minus 0.2% over the last 3 years, thanks to EBITDA generation, operational cash flow improvement.

We observed over the last quarter a positive working cap variation because the last year variation was negatively impacted by the reimbursement of French state advances, which was not the case this year. We also continue to work on the French DSO to reduce our delays. This has been combined with a selective CapEx policy, 4% of growth CapEx on revenues this quarter, stable versus last year with a clear priority on high investments and on strategic priorities. So we further develop imaging radiotherapy, and we also dedicate our CapEx to portfolio management initiatives.

Regarding the financing, so a key update of the quarter. Obviously, in July 2026, we need to mention the completion of the refinancing of our senior debt, EUR 1.75 billion, including EUR 200 million RCF undrawn. We pushed our senior debt maturities to 2033 and simplified our balance sheet structures as well, providing higher flexibility. We also recharged our real estate financing on HP Dijon-Bourgogne in France, drawing a new tranche of Fiducie structured loan. It's an illustration on how real estate is a way to secure good financing at attractive conditions. And maybe a last update on our hedging policy in a context where we see the interest rate increasing. We proactively manage and we optimize our hedging policy. Today, 80% of our gross financial debt is hedged again versus to hedge and face the context of increasing interest rates. So as a conclusion, good start of the year, both in terms of ability to secure organic growth translation into financial performance and delevering.

A word on the key perspective for the months to come. So first of all, executing -- sorry, if we move to next page, Page 12, yes, executing the performance plan, clearly, it's a priority, delivering the new strategy, sustaining top line growth, notably by leveraging our integrated health care offering, maintaining high standards of care, enhancing the medical outcome. And all of this, combined with a strict capital allocation will contribute to deleverage the company.

As announced by Pascal, if we move to the Page 13, we maintain and we confirm our guidance for the short and the midterm. FY '27 revenue growth between 2% and 3% at constant FX and stable EBITDA margin versus last year. By FY '29, revenue growth at 3% CAGR per annum and gradual EBITDA margin improvement, growth CapEx at 4% of our revenue on average over the next 3 years and continued deleveraging targeting a ratio net debt on EBITDA pre-IFRS below 4.0.

Thank you for your attention. And Pascal and I will be happy to take any of your questions.

Pascal Roche Dirección

Okay. Thanks, Clement. And so as just stated, please feel free regarding any questions you may have.

Operator

[Operator Instructions] Our first question comes from the line of Craig Wong-Pan from RBC.

Preguntas y respuestas

Craig Wong-Pan Analista

I just wanted to ask about the net debt. Like I understand the leverage ratio usually increases from June to September due to seasonality. But if you just look at the net debt figure, that also increased by about EUR 145 million from June to September. Could you just explain why that's increased?

Pascal Roche Dirección

Yes, sure. Thank you for your question. I think when we compare with June, we have to consider the seasonality effect of our activities. Traditionally, we know that in the first quarter of the year, so we have 2 months -- 2 summer months where, again, the patients do not undertake specific surgeries that are nonemergency, I would say, needs. So we know the activity is lower. So usually, our first quarter of the year, net debt increased versus June. But again, we need to compare September with September. So that's why we presented this vision, I think, on the Page #11 of the presentation, which shows -- Page 10, sorry, which shows a decrease in the level of net debt versus last year and versus 2 years ago. So again, seasonality is the right answer to your question, I think.

Operator

[Operator Instructions].

Clement Lafaix Dirección

If I may, so while we are waiting for maybe some questions. So we have received a couple of written questions. So maybe to deal with some of them. One of the question is, how do we explain that in spite of admission growth for France, 4.1%, the revenue growth is a bit lower. What is true, by the way, we are more in the range of 2.4%.

Well, the first -- there are 2 reasons, I would say. The first one is the activity mix. The surgery keep on increasing versus inpatient. Just to remind that for the last -- during the last 12 years regarding surgery for Ramsay Sante in France, we have been growing from 49% of day surgery to 74% of day surgery, which means that today, many, many surgeries, the patient is leaving the hospital the same day, whereas 12 years ago, he was spending maybe 1 or 2 nights in the hospital. And long story short, day surgery in average is less paid than inpatient surgery. So there is this activity mix value, which is the first driver. The second driver is that the tariff has been very constrained, even, by the way, decreasing in some specialties such as imaging. So these 2 factors combined explain, if I may, why the MSO admission for France 4.1% does not translate exactly in a 4.1% revenue growth.

There is another -- by the way, there is a couple of same questions regarding the day medicine for France, just to explain what is it. So the day medicine has been promoted, I would say, approved by the French government in order to initiate pathway the same day. So there are many day medicine pathway, e.g. obesity, e.g. pain management, et cetera, et cetera. And if you see the right 4 specialists, the same day can be a doctor, a physio, et cetera, et cetera. But as long as you see the 4 specialist the same day in the same unit, you are paid, I would say, by a better price, a much better price. So it's a huge need from a patient standpoint, and it has, I would say, a very positive economic impact for the company. So yes, we are running -- we are growing, I would say, on this specific segment, not double digit, but really in the range of 35% to 40%.

We have a next question regarding cost initiatives. elaborate on these initiatives? And should we expect nonrecurring cost for those initiatives?

So we will turn every stone clearly behind the different lines of the P&L. But clearly, we are working on every caption, I would say, of the cost being personnel cost, adapting the actual staffing to activity, reducing temp staff, reducing nonmedical staff as well increasing our productivity. Regarding medical purchases, we have also a couple of initiatives to centralize and make sure we optimize the cost per reference, working notably in France with doctors to make sure to reduce the number of reference and increase and improve our purchasing conditions.

Within the performance initiatives, we not only have cost but also some mix improvement initiatives regarding the coding accuracy. Regarding you mentioned Pascal, which is clearly also a way to improve also our mix in terms of margin because we believe this kind of pathways are to our margins. So behind the performance plans, we also find the portfolio management initiatives that are, as you know, a very important part of the strategic plan Connecting Care 2030. Behind this portfolio management, we might have a couple of nonrecurring costs to implement these measures, but we believe these costs will remain quite limited because basically, it's about to optimize our portfolio and to -- and again, to reduce when we can the footprint and to accelerate on the segments that are more profitable.

Pascal Roche Dirección

Yes. Thanks, Clement. There are 4, if not 5 questions regarding the budget for France for next year and the health care budget.

Well, what we can say is that there is currently as of today, a total budget and uncertainty in France. The dedicated health care budget for 2027 for France called PLFSS has been, by the way, rejected 2 days ago. So back to the parliament. First, I mean, Ramsay Sante, of course, we don't speculate, I would say, on political outcomes. But we don't know, nobody knows. That being said, by definition, we are always engaged actively with health care authority and policymaker, I would say, to advocate and just to remind that the private health care provider in France has systemic backbone of -- regarding the French system.

Now I think it's worth to share with you once again, as we did during the CMD that Ramsay Sante outlook does not rely solely, I would say, on tariff support we've got multiple levers within our hands, I would say, within management control being the volumes, the capacity utilization, the procurement, the workforce management and productivity beyond, of course, the fact that outside of France, the other country represents now 1/3 of the total activity with at least here a clear visibility. So we don't know. It's a short answer. But once again, we are concentrated in what is in the hands, I would say.

Clement Lafaix Dirección

We have a specific question regarding the CapEx, 4% of our revenues. Does it include greenfield? Or is it just maintenance CapEx?

So 4% is the total gross CapEx before the leasing that we implement to finance notably the imaging equipment. So 4% growth CapEx is the total bearing in mind that approximately 3% is regarding -- related to maintenance, IT and regulatory and 1% on average is dedicated to development and that's this pocket of development CapEx that we will dedicate to our strategic priorities.

We have one question regarding real estate. How much do we own? How much debt associated with this real estate?

So as we discussed during the CMD, so real estate is valued EUR 1.5 billion at the end of June. It represents 20% of our square meters operated within the group, located in France, 2 half of it being located in prime locations such as Paris region. And thanks to this real estate, we have been able to draw approximately EUR 350 million of real estate debt, and this amount has slightly increased at the end of September to roughly EUR 400 million after the refinancing of the HP Dijon Bourgogne that I mentioned earlier in this presentation.

Pascal Roche Dirección

Okay. Thanks, Clement. Any other questions?

Operator

[Operator Instructions] No further questions by the phone lines.

Pascal Roche Dirección

Okay. Thanks a lot. So I think we have tried to cover the written questions we have received. I hope so at least with Clement. Well, thanks once again for having joined this morning our Q1 results. And as always, I would say, we stay at your disposal. Would you have some specific questions, we'll do our best to answer. Thanks once again, and have a very good day. Bye-bye.

Clement Lafaix Dirección

Thank you.

Operator

Thank you. This concludes today's conference call. Thank you for participating, and you may now disconnect.